Trial to Evaluate Safety and Tolerability of ALN-TTR01 in Transthyretin (TTR) Amyloidosis

Inclusion Criteria: * Diagnosis of TTR amyloidosis * Adequate blood counts, liver and renal function * Women of child-bearing potential must have a negative pregnancy test, cannot be breast feeding, and must use an adequate method of birth control * Males agree to use appropriate contraception * Willing and able to comply with protocol-required visit schedule and visit requirements and provide written informed consent. Exclusion Criteria: * Known human immunodeficiency virus (HIV) positive status * Receiving antibiotics for bacterial infection within 7 days of screening * Known or suspected systemic viral, parasitic or fungal infection * Receiving an investigational agent within 30 days prior to study drug administration * Poor cardiac function * Considered unfit for the study by the Principal Investigator * Known sensitivity to oligonucleotides * Employee or family member of the sponsor or the clinical study site personnel.